Literature DB >> 17505206

The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: three years after testing.

Veronica R Collins1, Bettina Meiser, Obioha C Ukoumunne, Clara Gaff, D James St John, Jane L Halliday.   

Abstract

BACKGROUND: To fully assess predictive genetic testing programs, it is important to assess outcomes over periods of time longer than the 1-year follow-up reported in the literature.
METHODS: We conducted a 3-year study of individuals who received predictive genetic test results for previously identified familial mutations in Australian Familial Cancer Clinics. Questionnaires were sent before attendance at the familial cancer clinic and 2 weeks, 4 months, 1 year, and 3 years after receiving test results. Psychological measures were included each time, and preventive behaviors were assessed at baseline and 1 and 3 years. Psychological measures were adjusted for age, gender, and baseline score.
RESULTS: The study included 19 carriers and 54 non-carriers. We previously reported an increase in mean cancer-specific distress in carriers at 2 weeks with a return to baseline levels by 12 months. This level was maintained until 3 years. Non-carriers showed sustained decreases after testing with a significantly lower level at 3 years compared with baseline (P < 0.001). These scores tended to be lower than those for carriers at 3 years (P = 0.09). Mean depression and anxiety scores did not differ between carriers and non-carriers and, at 3 years, were similar to baseline. All carriers and 7% of non-carriers had had a colonoscopy by 3 years, and 69% of 13 female carriers had undergone gynecological screening in the previous 2 years. Prophylactic surgery was rare.
CONCLUSION: This report of long-term data indicates appropriate screening and improved psychological measures for non-carriers with no evidence of undue psychological distress in carriers of hereditary nonpolyposis colorectal cancer mutations.

Entities:  

Mesh:

Year:  2007        PMID: 17505206     DOI: 10.1097/gim.0b013e31804b45db

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  44 in total

1.  Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options.

Authors:  Jacqueline Duffour; Audrey Combes; Evelyne Crapez; Florence Boissière-Michot; Frédéric Bibeau; Pierre Senesse; Marc Ychou; Julie Courraud; Hélène de Forges; Lise Roca
Journal:  J Genet Couns       Date:  2015-09-22       Impact factor: 2.537

2.  Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men.

Authors:  Aubrey R Turner; Brian R Lane; Dan Rogers; Isaac Lipkus; Kathryn Weaver; Suzanne C Danhauer; Zheng Zhang; Fang-Chi Hsu; Sabrina L Noyes; Tamara Adams; Helga Toriello; Thomas Monroe; Trudy McKanna; Tracey Young; Ryan Rodarmer; Richard J Kahnoski; Mouafak Tourojman; A Karim Kader; S Lilly Zheng; William Baer; Jianfeng Xu
Journal:  Cancer       Date:  2016-07-19       Impact factor: 6.860

3.  Screening adherence and cancer risk perceptions in colorectal cancer survivors with Lynch-like syndrome.

Authors:  L H Katz; A M Burton-Chase; S Advani; B Fellman; K M Polivka; Y Yuan; P M Lynch; S K Peterson
Journal:  Clin Genet       Date:  2015-09-14       Impact factor: 4.438

4.  Choosing not to undergo predictive genetic testing for hereditary colorectal cancer syndromes: expanding our understanding of decliners and declining.

Authors:  Louise A Keogh; Heather Niven; Alison Rutstein; Louisa Flander; Clara Gaff; Mark Jenkins
Journal:  J Behav Med       Date:  2017-02-14

5.  Development and validation of an instrument to measure the impact of genetic testing on self-concept in Lynch syndrome.

Authors:  M J Esplen; N Stuckless; S Gallinger; M Aronson; H Rothenmund; K Semotiuk; J Stokes; C Way; J Green; K Butler; H V Petersen; J Wong
Journal:  Clin Genet       Date:  2011-10-03       Impact factor: 4.438

6.  Preferences regarding targeted education and risk assessment in people with a family history of major depressive disorder.

Authors:  Veronica Quinn; Bettina Meiser; Alex Wilde; Zoe Cousins; Kristine Barlow-Stewart; Philip B Mitchell; Peter R Schofield
Journal:  J Genet Couns       Date:  2014-01-10       Impact factor: 2.537

7.  Effect of direct-to-consumer genomewide profiling to assess disease risk.

Authors:  Cinnamon S Bloss; Nicholas J Schork; Eric J Topol
Journal:  N Engl J Med       Date:  2011-01-12       Impact factor: 91.245

8.  The Impact of Receiving Predictive Genetic Information about Lynch Syndrome on Individual Colonoscopy and Smoking Behaviors.

Authors:  Joanne Soo-Min Kim; Peter C Coyte; Michelle Cotterchio; Louise A Keogh; Louisa B Flander; Clara Gaff; Audrey Laporte
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-08-15       Impact factor: 4.254

9.  Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease.

Authors:  Astrid Rasmussen; Elisa Alonso; Adriana Ochoa; Irene De Biase; Itziar Familiar; Petra Yescas; Ana-Luisa Sosa; Yaneth Rodríguez; Mireya Chávez; Marisol López-López; Sanjay I Bidichandani
Journal:  BMC Med Genet       Date:  2010-01-12       Impact factor: 2.103

Review 10.  Genetic testing for Lynch syndrome in the first year of colorectal cancer: a review of the psychological impact.

Authors:  Karin M Landsbergen; Judith B Prins; Han G Brunner; Floris W Kraaimaat; Nicoline Hoogerbrugge
Journal:  Fam Cancer       Date:  2009-03-28       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.